Introduction: Pathogenesis in a subgroup of sarcopenic patients seems to be based on a reduced number of motor neurons. This study aimed at investigating the overlap between sarcopenia and neurodegeneration, as reflected by a low number of motor neurons in patients with Parkinsonian syndromes (PS). Methods: The motor unit number index (MUNIX) of the hypothenar muscle was used to assess the number and size (MUSIX) of motor units (MUs) in patients with idiopathic Parkinson disease (iPD, n = 53), patients with atypical Parkinsonian syndrome (aPS, n = 21), and a control group (n = 30). Mean age of participants was 70.3 years and 54.1% were female. Skeletal muscle mass by bioelectrical impedance analysis, hand-grip strength and gait speed were measured. Based on these assessments, sarcopenia was diagnosed according to the criteria of the European Working Group on Sarcopenia in Older People. Results: Sarcopenia criteria were met by 10 patients with PS (13.5%). The study group had significantly lower MUNIX values than the control group (109 [SD ±39.1] vs. 129 [SD ±45.1]; p = 0.020) even after adjustment for age and sex. Three of the 5 sarcopenic iPD patients (75%) had pathological low MUNIX values (<80). Discussion/Conclusion: Sarcopenia is a frequent comorbidity in PS. The pathologically low MUNIX values found in 75% of our sarcopenic iPD patients provides further support for the existence of a neurodegenerative overlap syndrome with a reduced number of MUs potentially leading to sarcopenia. This finding warrants further evaluation.

1.
World Health Organisation
.
World report on ageing and health
.
Geneva
:
WHO Press
;
2015
. p.
43
.
2.
Phillips
A
,
Strobl
R
,
Vogt
S
,
Ladwig
KH
,
Thorand
B
,
Grill
E
.
Sarcopenia is associated with disability status-results from the KORA-Age study
.
Osteoporos Int
.
2017
Jul
;
28
(
7
):
2069
79
.
[PubMed]
0937-941X
3.
Drey
M
,
Krieger
B
,
Sieber
CC
,
Bauer
JM
,
Hettwer
S
,
Bertsch
T
, et al.;
DISARCO Study Group
.
Motoneuron loss is associated with sarcopenia
.
J Am Med Dir Assoc
.
2014
Jun
;
15
(
6
):
435
9
.
[PubMed]
1525-8610
4.
Drey
M
,
Hasmann
SE
,
Krenovsky
JP
,
Hobert
MA
,
Straub
S
,
Elshehabi
M
, et al.
Associations between early markers of Parkinson’s disease and sarcopenia
.
Front Aging Neurosci
.
2017
Mar
;
9
(
MAR
):
53
.
[PubMed]
1663-4365
5.
Postuma
RB
,
Berg
D
,
Stern
M
,
Poewe
W
,
Olanow
CW
,
Oertel
W
, et al.
MDS clinical diagnostic criteria for Parkinson’s disease
.
Mov Disord
.
2015
Oct
;
30
(
12
):
1591
601
.
[PubMed]
0885-3185
6.
Poewe
W
,
Seppi
K
,
Tanner
CM
, et al.
Parkinson disease - only suppl info 1: imaging biomarkers. Nat Rev Dis Prim.
2017
. doi:
7.
Sailer
A
,
Molnar
GF
,
Paradiso
G
,
Gunraj
CA
,
Lang
AE
,
Chen
R
.
Short and long latency afferent inhibition in Parkinson’s disease
.
Brain
.
2003
Aug
;
126
(
Pt 8
):
1883
94
.
[PubMed]
0006-8950
8.
Caviness
JN
,
Smith
BE
,
Clarke Stevens
J
,
Adler
CH
,
Caselli
RJ
,
Hentz
JG
, et al.
Motor unit number estimates in idiopathic Parkinson’s disease
.
Parkinsonism Relat Disord
.
2002
Jan
;
8
(
3
):
161
4
.
[PubMed]
1353-8020
9.
Uitti
RJ
,
Berry
K
,
Yasuhara
O
,
Eisen
A
,
Feldman
H
,
McGeer
PL
, et al.
Neurodegenerative ‘overlap’ syndrome: clinical and pathological features of Parkinson’s disease, motor neuron disease, and Alzheimer’s disease
.
Parkinsonism Relat Disord
.
1995
Jul
;
1
(
1
):
21
34
.
[PubMed]
1353-8020
10.
Barichella
M
,
Pinelli
G
,
Iorio
L
,
Cassani
E
,
Valentino
A
,
Pusani
C
, et al.
Sarcopenia and Dynapenia in Patients With Parkinsonism
.
J Am Med Dir Assoc
.
2016
Jul
;
17
(
7
):
640
6
.
[PubMed]
1525-8610
11.
Tan
AH
,
Hew
YC
,
Lim
SY
,
Ramli
NM
,
Kamaruzzaman
SB
,
Tan
MP
, et al.
Altered body composition, sarcopenia, frailty, and their clinico-biological correlates, in Parkinson’s disease
.
Parkinsonism Relat Disord
.
2018
Nov
;
56
:
58
64
.
[PubMed]
1353-8020
12.
Vetrano
DL
,
Pisciotta
MS
,
Laudisio
A
,
Lo Monaco
MR
,
Onder
G
,
Brandi
V
, et al.
Sarcopenia in Parkinson Disease: Comparison of Different Criteria and Association With Disease Severity
.
J Am Med Dir Assoc
.
2018
Jun
;
19
(
6
):
523
7
.
[PubMed]
1525-8610
13.
Yazar
T
,
Yazar
HO
,
Zayimoğlu
E
,
Çankaya
S
.
Incidence of sarcopenia and dynapenia according to stage in patients with idiopathic Parkinson’s disease
.
Neurol Sci
.
2018
Aug
;
39
(
8
):
1415
21
.
[PubMed]
1590-1874
14.
Peball
M
,
Mahlknecht
P
,
Werkmann
M
,
Marini
K
,
Murr
F
,
Herzmann
H
, et al.
Prevalence and associated factors of sarcopenia and frailty in Parkinson’s disease: A cross-sectional study
.
Gerontology
.
2019
;
65
(
3
):
216
28
.
[PubMed]
0304-324X
15.
Liu
A
,
Bui
T
,
Van Nguyen
H
,
Ong
B
,
Shen
Q
,
Kamalasena
D
.
Serum C-reactive protein as a biomarker for early detection of bacterial infection in the older patient
.
Age Ageing
.
2010
Sep
;
39
(
5
):
559
65
.
[PubMed]
0002-0729
16.
Janssen
I
,
Heymsfield
SB
,
Baumgartner
RN
,
Ross
R
.
Estimation of skeletal muscle mass by bioelectrical impedance analysis
.
J Appl Physiol (1985)
.
2000
Aug
;
89
(
2
):
465
71
.
[PubMed]
8750-7587
17.
Kemmler
W
,
Froehlich
M
,
von Stengel
S
,
Kleinöder
H
.
Whole-Body Electromyostimulation – The Need for Common Sense! Rationale and Guideline for a Safe and Effective Training
.
Dtsch Z Sportmed
.
2016
;
2016
(
09
):
218
21
. 0344-5925
18.
Nandedkar
SD
,
Barkhaus
PE
,
Stålberg
EV
.
Motor unit number index (MUNIX): principle, method, and findings in healthy subjects and in patients with motor neuron disease
.
Muscle Nerve
.
2010
Nov
;
42
(
5
):
798
807
.
[PubMed]
0148-639X
19.
Cotzias
GC
,
Yahr
MD
,
Duvoisin
RC
, et al.
Metabolic responses to levodopa
.
N Engl J Med
.
1972
Dec
;
287
(
25
):
1302
3
.
[PubMed]
0028-4793
20.
Adams
F
,
Boschmann
M
,
Lobsien
E
,
Kupsch
A
,
Lipp
A
,
Franke
G
, et al.
Influences of levodopa on adipose tissue and skeletal muscle metabolism in patients with idiopathic Parkinson’s disease
.
Eur J Clin Pharmacol
.
2008
Sep
;
64
(
9
):
863
70
.
[PubMed]
0031-6970
21.
Höglinger
GU
,
Respondek
G
,
Stamelou
M
,
Kurz
C
,
Josephs
KA
,
Lang
AE
, et al.;
Movement Disorder Society-endorsed PSP Study Group
.
Clinical diagnosis of progressive supranuclear palsy: the movement disorder society criteria
.
Mov Disord
.
2017
Jun
;
32
(
6
):
853
64
.
[PubMed]
0885-3185
22.
Bourinaris
T
,
Houlden
H
.
C9orf72 and its Relevance in Parkinsonism and Movement Disorders: A Comprehensive Review of the Literature
.
Mov Disord Clin Pract (Hoboken)
.
2018
Nov
;
5
(
6
):
575
85
.
[PubMed]
2330-1619
23.
Kanda
K
,
Hashizume
K
.
Recovery of motor-unit function after peripheral nerve injury in aged rats
.
Neurobiol Aging
.
1991
Jul-Aug
;
12
(
4
):
271
6
.
[PubMed]
0197-4580
24.
Pinelli
P
,
Pisano
F
,
Ceriani
F
,
Miscio
G
.
EMG evaluation of motor neuron sprouting in amyotrophic lateral sclerosis
.
Ital J Neurol Sci
.
1991
Aug
;
12
(
4
):
359
67
.
[PubMed]
0392-0461
25.
Brown
MC
,
Holland
RL
,
Hopkins
WG
.
Motor Nerve Sprouting
.
Annu Rev Neurosci
.
2003
;
•••
:
[PubMed]
0147-006X
26.
Porritt
M
,
Stanic
D
,
Finkelstein
D
,
Batchelor
P
,
Lockhart
S
,
Hughes
A
, et al.
Dopaminergic innervation of the human striatum in Parkinson’s disease
.
Mov Disord
.
2005
Jul
;
20
(
7
):
810
8
.
[PubMed]
0885-3185
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.